Low-Dose Naltrexone Use in Biopsy-Proven Lichen Planus of the Nails

JAMA Dermatology, JAMA Network October 30, 2024 Low-Dose Naltrexone Use in Biopsy-Proven Lichen Planus of the Nails Eric R. Bray, MD PhD; Brian W. Morrison, MD https://jamanetwork.com/journals/jamadermatology/article-abstract/2825430 Key Points Question:  Is low-dose naltrexone effective in treating nail lichen planus? Findings:  In this single tertiary referral center case series of 7 patients with biopsy-proven nail lichen […]

Suzanne Rosenberg, RPh – LDN Radio Show; July 2023 (LDN; low dose naltrexone)

  Linda Elsegood: Welcome to the LDN Radio Show brought to you by the LDN Research Trust. I’m your host Linda Elsegood. Today I’d like to welcome our guest Pharmacist Suzanne Rosenberg from Community Compounding Pharmacy in Oregon.  So could you tell us what made you decide to become a pharmacist?  Suzanne Rosenberg: When I […]

Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa-associated refractory pruritus (Abstract)

Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa-associated refractory pruritus Case Reports; JAAD Case Rep 19 June 2023 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339115/ A rare subtype of epidermolysis bullosa, epidermolysis bullosa pruriginosa (EBP) is characterized by severely pruritic lichenified and hypertrophic prurigo-like nodules and plaques secondary to chronic itching. No standard first-line therapy currently exists. Reported is a case of […]

Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris… (News)

Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris… Cureus 24 January 2023 https://www.cureus.com/articles/132544-oral-low-dose-naltrexone-in-the-treatment-of-frontal-fibrosing-alopecia-and-lichen-planopilaris-an-uncontrolled-open-label-prospective-study#!/ Frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) is scarring alopecias with limited evidence supporting their treatment options. We investigated the use of low-dose naltrexone (3 mg oral daily) as adjunctive therapy in the treatment of FFA […]